HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal

Health Medical Technology & Services Written by: Ephrem Joseph 08:27 Thu 03 Sep 2026 --> Disclaimer No investment advice About this content Editorial Standards & Policies Share article About this content × About Ephrem Joseph Ephrem began his journalistic journey at Proactive in June 2021. With a strong academic background in Information Technology, his expertise particularly lies in the field of Cyber Security, Management Information Systems and Computer Forensics. Before joining Proactive, Ephrem worked as a researcher and lecturer at a number of leading universities, including the University of Portsmouth's Institute of Criminal Justice Studies, the University of Winchester’s Institute of Policing, and Jain... Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Use of technology Proactive has always been a forward looking and enthusiastic technology adopter. Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows. Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. Hutchmed (China) Ltd ( AIM:HCM NASDAQ:HCM HKG:0013 ) View Price & Profile HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal Published: 08:27 03 Sep 2026 BST Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares jumped 17% to 210p on Thursday after the oncology specialist struck a licensing agreement with GSK worth up to US$1.295 billion for its experimental KRAS-EGFR cancer therapy. The shares were up 30.5p from Wednesday’s 179.5p close following news that GSK will receive exclusive rights outside Mainland China, Hong Kong, Macau and Taiwan to develop and commercialise HMPL-A830. HUTCHMED will receive US$110 million upfront and could earn a further US$1.185 billion in development, regulatory and commercial milestone payments, alongside tiered royalties on net sales. HMPL-A830 is a first-in-class antibody-targeted therapy conjugate designed to deliver a KRAS inhibitor directly to EGFR-expressing tumours while simultaneously blocking EGFR and KRAS signalling. Initial clinical development will target colorectal, pancreatic and lung cancers, with a global Phase I programme expected to begin in the second half of 2026. HUTCHMED will lead the Phase I programme before GSK assumes responsibility for subsequent development and commercialisation outside Greater China. Acting chief executive Johnny Cheng said the agreement marked “a significant step” in maximising HMPL-A830’s potential and represented the first global licensing deal from HUTCHMED’s ATTC platform. GSK oncology research head Hesham Abdullah said HMPL-A830’s dual KRAS-EGFR mechanism “has the potential to significantly improve upon current standard of care”. HUTCHMED will retain full development and commercialisation rights in Mainland China, Hong Kong, Macau and Taiwan. Continue reading